XML 28 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Net revenue $ 46,743 $ 38,034 $ 31,317
Operating costs and expenses:      
Cost of revenue 15,681 10,797 3,634
Research and development 12,746 9,054 9,201
Selling, general and administrative 119,641 64,895 50,582
Intangible amortization 4,106 3,922 3,738
Total operating costs and expenses 152,174 88,668 67,155
Loss from operations (105,431) (50,634) (35,838)
Other (income) expense:      
Loss (gain) on derivative liability 512 (8,310) 300
Change in fair value of debt and liability instruments 7,189 0 0
(Gain) loss on debt extinguishment, net 0 (28,634) 12,463
Scilex Pharma Notes principal increase 0 0 28,000
Interest expense, net 1,068 9,604 11,764
Loss on foreign currency exchange 118 66 54
Total other (income) expense 8,887 (27,274) 52,581
Loss before income taxes (114,318) (23,360) (88,419)
Income tax expense 13 4 5
Net loss $ (114,331) $ (23,364) $ (88,424)
Earnings Per Share [Abstract]      
Net loss per share attributable to common stockholders - basic $ (1.28) $ (0.17) $ (0.67)
Net loss per share attributable to common stockholders - diluted $ (1.28) $ (0.17) $ (0.67)
Weighted Average Number of Shares Outstanding, Diluted [Abstract]      
Weighted average number of shares during the period-basic 130,298 134,226 132,858
Weighted average number of shares during the period -diluted 130,298 134,226 132,858